All In Biotech

Drug Trial Radar · NCT03617731

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 662 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

662

Actual

Start

Oct 18, 2018

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
University of Heidelberg Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment

Conditions

  • Multiple Myeloma

Interventions

  • LenalidomideDrug

    25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)

  • BortezomibDrug

    all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles

  • DexamethasoneDrug

    20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.

  • IsatuximabDrug

    10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRD negativity after induction Treatment (comparison of arms IA and IB)Time frame: 18 weeks after start of study treatment
  2. Progression Free Survival (PFS) after second randomization (arms IIA and IIB)Time frame: time from 2. randomization to progression or death from any cause whichever comes first, censored after three years of maintenance therapy

Locations

72 sites in 1 country. Site status is shown where the registry gives one.

  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation

    Aachen, Germany

  • Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin

    Bad Saarow, Germany

  • Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie)

    Berlin, Germany

  • Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie

    Berlin, Germany

  • HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie

    Berlin, Germany

  • Studiengesellschaft Onkologie Bielefeld GbR

    Bielefeld, Germany

  • Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin

    Bielefeld, Germany

  • Medizinische Universitätsklinik, Knappschaftskrankenhaus

    Bochum, Germany

  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie

    Bonn, Germany

  • Johanniter Krankenhaus Bonn

    Bonn, Germany

  • Zentrum für ambulante Hämatologie und Onkologie (ZAHO)

    Bonn, Germany

  • Städtisches Klinikum Braunschweig, Med. Klinik III, Hämatologie und Onkologie

    Braunschweig, Germany

  • Klinikum Chemnitz GmbH, Innere Medizin III

    Chemnitz, Germany

  • Uniklinik Köln, Klinik I für Innere Medizin

    Cologne, Germany

  • Carl-Thiem-Klinikum Cottbus gGmbH, II. Medizinische Klinik

    Cottbus, Germany

  • Onkologisches Studienzentrum Darmstadt

    Darmstadt, Germany

  • Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie

    Darmstadt, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden, an der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I

    Dresden, Germany

  • HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf

    Duisburg, Germany

  • Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatologie und Palliativmedizin

    Düsseldorf, Germany

  • Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie

    Düsseldorf, Germany

  • Universitätsklinik Erlangen

    Erlangen, Germany

  • St. Antonius-Hospital Eschweiler, Klinik für Hämatologie / Onkologie

    Eschweiler, Germany

  • Universitätsklinikum Essen, Klinik für Hämatologie

    Essen, Germany

  • Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation

    Essen, Germany

  • Gemeinschaftspraxis Prof. Dr. Michael Kiehl und Dipl. Med. Wolfgang Stein

    Frankfurt (Oder), Germany

  • Klinikum Frankfurt (Oder) GmbH

    Frankfurt (Oder), Germany

  • Centrum für Hämatologie und Onkologie Bethanien

    Frankfurt am Main, Germany

  • Agaplesion Markus Krankenhaus, Med. Klinik I

    Frankfurt am Main, Germany

  • Krankenhaus Nordwest, Institut für Klinisch-Onkologische Forschung

    Frankfurt am Main, Germany

  • Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II

    Frankfurt am Main, Germany

  • Klinikum Fulda, Klinisches Studienzentrum GmbH

    Fulda, Germany

  • Universitätsklinik der Justus-Liebig-Universität, Medizinische Klinik IV

    Giessen, Germany

  • Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital Goch, Klinik für Hämatologie - Onkologie

    Goch, Germany

  • Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie

    Hagen, Germany

  • Asklepios Klinik Hamburg St. Georg

    Hamburg, Germany

  • Universitätsklinikum Hamburg Eppendorf, Zentrum für Onkologie, Studienzentrale der II. Medizinischen Klinik

    Hamburg, Germany

  • Asklepios Klinik Hamburg Altona, II. Med. Klinik

    Hamburg, Germany

  • Immunologisch-onkologisches MVZ am Siloah Krankenhaus

    Hanover, Germany

  • KRH Klinikum Siloah, Klinik für Hämatologie und Onkologie

    Hanover, Germany

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.